塞拉斯生命科学
SLS
9.98
-1.36
-11.99%
塞拉斯生命科学
US · SLS
#2687 按市值排名
上市于 1970
9.98
-1.36
-11.99%
实时 - 追踪5344个代码 - 心跳于335秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了5家。
- 机构持股总比例下降了0.6个百分点。
机构持股
- 机构持股比例
- 36.69% -0.57pp
- 机构数量
- 222 +5
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund29.67%
Hedge Fund2.66%
Private Company2.15%
Public Company1.71%
Individual/Insider0.39%
Government Pension Fund0.29%
Family Office/Trust0.20%
Other62.91%
主要股东 截至 2026-06-30
BlackRock
7.46% · 15.07M 股
State Street Global Advisors
6.44% · 13.00M 股
Vanguard Capital Management, LLC
4.73% · 9.56M 股
Geode Capital Management, LLC
2.42% · 4.88M 股
Anson Group
2.23% · 4.50M 股
Edward Jones Trust Company
1.14% · 2.30M 股
Vanguard Portfolio Management, LLC
1.07% · 2.16M 股
Susquehanna International Group, LLP
1.02% · 2.05M 股
Northern Trust Global Investments
0.80% · 1.62M 股
UBS Asset Management
0.76% · 1.53M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 41次买入 · 6次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Angelos Stergiou | Chief Executive Officer | 0.15% |
| John Burns | Senior Vice President | 0.07% |
| Dragan Cicic | Senior Vice President of Clinical Development | 0.06% |
| Katherine Kalin | Independent Director | 0.05% |
| Jane Wasman | Independent Chairperson | 0.02% |
| Robert Van Nostrand | Independent Director | 0.02% |
| David Scheinberg | Independent Director | 0.01% |
| John Varian | Independent Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-06-15 | Angelos Stergiou | Chief Executive Officer | Other Acquisition | +1,065,000 | -- |
| 2026-01-06 | Robert Van Nostrand | Independent Director | Other Acquisition | +50,000 | -- |
| 2026-01-06 | John Varian | Independent Director | Other Acquisition | +50,000 | -- |
| 2026-01-06 | David Scheinberg | Independent Director | Other Acquisition | +50,000 | -- |
| 2026-01-06 | Jane Wasman | Independent Chairperson | Other Acquisition | +50,000 | -- |
| 2026-01-06 | Dragan Cicic | Senior Vice President of Clinical Development | Other Acquisition | +300,000 | -- |
| 2026-01-06 | John Burns | Senior Vice President | Other Acquisition | +300,000 | -- |
| 2026-01-06 | Katherine Kalin | Independent Director | Other Acquisition | +50,000 | -- |
| 2025-12-02 | Dragan Cicic | Senior Vice President of Clinical Development | Other Disposition | -63,800 | $1.50 |
| 2025-12-02 | Angelos Stergiou | Chief Executive Officer | Other Disposition | -187,066 | $1.50 |
| 2025-12-02 | John Burns | Senior Vice President | Other Disposition | -58,592 | $1.50 |
| 2025-11-18 | Katherine Kalin | Independent Director | Open Market Acquisition | +63,400 | $1.59 |
| 2025-06-11 | Robert Van Nostrand | Independent Director | Open Market Acquisition | +10,000 | $1.48 |
| 2025-05-29 | Jane Wasman | Independent Chairperson | Open Market Acquisition | +20,000 | $1.69 |
| 2025-05-21 | Katherine Kalin | Independent Director | Open Market Acquisition | +20,000 | $1.80 |
| 2025-01-09 | Robert Van Nostrand | Independent Director | Other Acquisition | +12,500 | -- |
| 2025-01-09 | Robert Van Nostrand | Independent Director | Other Derivative Acquisition | +18,500 | $0.95 |
| 2025-01-09 | John Varian | Independent Director | Other Acquisition | +12,500 | -- |
| 2025-01-09 | John Varian | Independent Director | Other Derivative Acquisition | +18,500 | $0.95 |
| 2025-01-09 | David Scheinberg | Independent Director | Other Acquisition | +12,500 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:21 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
塞拉斯生命科学 讨论区 0 条评论